SYDNEY, Australia - Unfavorable results from clinical trials have stopped another collaborative project involving an Australian biotech company, despite favorable preclinical trials. BresaGen Ltd. and British Biotech plc abandoned a collaborative agreement to develop E21R as a treatment for acute myeloid leukemia (AML). (BioWorld International)